{
    "xml": "<topic id=\"PHP18400\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/tegafur-with-gimeracil-and-oteracil\" basename=\"tegafur-with-gimeracil-and-oteracil\" title=\"TEGAFUR WITH GIMERACIL AND OTERACIL\">\n<title>TEGAFUR WITH GIMERACIL AND OTERACIL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_927\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/tegafur\">Tegafur</xref>\n</p>\n<data name=\"vtmid\">21994011000001104</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_699299946\" title=\"Antimetabolites\">Antimetabolites</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP71954\" outputclass=\"drugAction\" rev=\"1.10\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tegafur is a prodrug of fluorouracil.</p>\n<p>Gimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71942\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of advanced gastric cancer when used in combination with cisplatin</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71959\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71964\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Dihydropyrimidine dehydrogenase deficiency</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71929\" outputclass=\"interactions\" rev=\"1.16\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (tegafur).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71908\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">neuropathy</ph>; <ph outputclass=\"sideEffect\">ocular toxicity</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71969\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during and for up to 6 months after treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71924\" outputclass=\"pregnancy\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71978\" outputclass=\"breastFeeding\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71917\" outputclass=\"renalImpairment\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose if creatinine clearance 30&#8211;50&#8239;mL/minute&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid if creatinine clearance less than 30&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71870\" outputclass=\"nationalFunding\" rev=\"1.10\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2012) that tegafur with gimeracil and oteracil (<i>Teysuno</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil and platinum triplet first-line regimen.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP18400-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tegafur-with-gimeracil-and-oteracil\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76019\" title=\"Capsule\" namespace=\"/drugs/tegafur-with-gimeracil-and-oteracil/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_927\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/tegafur\" title=\"Tegafur\" count=\"1\" rel=\"link\">Tegafur</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76019\" namespace=\"/drugs/tegafur-with-gimeracil-and-oteracil/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP18400",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/tegafur-with-gimeracil-and-oteracil",
    "basename": "tegafur-with-gimeracil-and-oteracil",
    "title": "TEGAFUR WITH GIMERACIL AND OTERACIL",
    "interactants": [
        {
            "id": "bnf_int_927",
            "label": "Tegafur"
        }
    ],
    "vtmid": "21994011000001104",
    "drugClassification": [
        "Antimetabolites"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Tegafur is a prodrug of fluorouracil.\n\nGimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa.",
                "html": "<p>Tegafur is a prodrug of fluorouracil.</p><p>Gimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of advanced gastric cancer when used in combination with cisplatin",
                        "html": "Treatment of advanced gastric cancer when used in combination with cisplatin"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Dihydropyrimidine dehydrogenase deficiency",
                "html": "Dihydropyrimidine dehydrogenase deficiency"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (tegafur).",
                "html": "<p>Appendix 1 (tegafur).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "neuropathy",
                        "html": "neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ocular toxicity",
                        "html": "ocular toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during and for up to 6 months after treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises effective contraception during and for up to 6 months after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose if creatinine clearance 30&#8211;50 mL/minute&#8212;consult product literature.",
                "html": "<p>Reduce dose if creatinine clearance 30&#8211;50&#8239;mL/minute&#8212;consult product literature.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid if creatinine clearance less than 30 mL/minute.",
                "html": "<p>Manufacturer advises avoid if creatinine clearance less than 30&#8239;mL/minute.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (August 2012) that tegafur with gimeracil and oteracil (Teysuno ) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil and platinum triplet first-line regimen.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (August 2012) that tegafur with gimeracil and oteracil (<i>Teysuno</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil and platinum triplet first-line regimen.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76019",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_927",
                "label": "Tegafur",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76019",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}